Financial Performance - The consolidated net profit attributable to the parent company for the year ended December 31, 2024, was -256,117,402.41 RMB, indicating a loss[5]. - The undistributed profits on a consolidated basis amounted to -354,193,915.51 RMB, while the parent company's undistributed profits were 15,702,223.45 RMB[5]. - Due to the negative net profit, the company will not distribute profits for the year 2024, pending approval from the shareholders' meeting[5]. - The company's operating revenue for 2024 was approximately ¥591.94 million, a decrease of 14.85% compared to ¥695.18 million in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥256.12 million, a significant decline from a profit of ¥32.28 million in 2023, representing a decrease of 893.31%[21]. - The basic earnings per share for 2024 was -¥1.86, down 908.70% from ¥0.23 in 2023[23]. - The net cash flow from operating activities improved by ¥75.47 million compared to the previous year, reaching -¥67.63 million in 2024[26]. - The company's total assets at the end of 2024 were approximately ¥2.49 billion, a decrease of 5.98% from ¥2.65 billion at the end of 2023[22]. - The company reported a significant increase in asset impairment provisions due to cautious management practices, impacting profit metrics[24]. - The company reported a net loss attributable to shareholders of 256.12 million yuan and a net loss of 261.38 million yuan after deducting non-recurring gains and losses, primarily due to deferred customer demand and increased R&D investments[109]. Research and Development - Research and development expenses accounted for 37.59% of operating revenue in 2024, an increase of 4.87 percentage points from 32.72% in 2023[23]. - The company invested heavily in R&D, focusing on medical AI technology and product iterations, which increased the technical content and market competitiveness of its products[35]. - The company applied for 53 new invention patents and obtained 13 invention patent authorizations during the reporting period, bringing the total number of authorized invention patents to 58[87]. - Total R&D investment amounted to ¥222,525,583.83, a decrease of 2.16% compared to the previous year, with R&D investment as a percentage of operating income increasing by 4.88 percentage points to 37.59%[88]. - The company has developed multiple specialized electronic medical record (EMR) products, including those for anesthesia, intensive care, and emergency medicine, enhancing its market position[100]. - The company has developed a cloud-native platform that enables automatic fault removal and reconstruction, showcasing strong self-healing capabilities and scalable deployment across multiple hospitals[86]. - The company is focusing on intelligent upgrades of electronic medical records, aiming for comprehensive leadership in depth, breadth, efficiency, and quality[155]. Market Position and Strategy - The company has maintained its leading position in the Chinese electronic medical record market for 10 consecutive years, ranking first in 2023[54]. - In the medical big data solutions market, the company has been in the top three for five consecutive years, further enhancing its market position and brand value[54]. - The company aims to drive high-quality hospital development through technology innovation and collaboration with major AI and computing power partners[53]. - The company is focused on developing advanced digital solutions to enhance patient care and streamline hospital management processes[92]. - The company is exploring mergers and acquisitions to strengthen its market position and diversify its product offerings[164]. - The company plans to enhance its market presence by enhancing product functionalities and user engagement through upgraded systems and new features[13]. - The company anticipates continued growth in the medical informationization sector driven by supportive government policies and a focus on clinical needs[146]. Risks and Compliance - The company has detailed potential risks in the report, which investors should consider[3]. - The company faces risks related to market competition, with a small market share in the overall medical informationization market, despite ranking first in the EMR segment and third in the medical big data solutions segment[112]. - The company has identified potential risks in customer expansion, project implementation without signed contracts, and seasonal fluctuations in performance due to project acceptance timing[114]. - The company has a risk of increased bad debt losses due to weak accounts receivable recovery capabilities from both medical institutions and third-party non-medical institutions[116]. - The company faces risks from changes in tax incentives, which could increase tax liabilities and adversely affect operating performance[118]. - The governance structure of the company is continuously being improved to ensure compliance with relevant laws and regulations[159]. Technological Innovations - The company is leveraging advanced AI capabilities to improve diagnostic accuracy and automate administrative processes, thereby reducing the burden on healthcare professionals[76]. - The company has developed a unified big data processing architecture that integrates various types of original data, facilitating efficient management and real-time analysis of massive datasets[17]. - The integration of new technologies such as AI, big data, and cloud computing is significantly improving the efficiency and effectiveness of medical information systems[79]. - The company is focusing on the integration of cloud computing, big data, artificial intelligence, and IoT to drive innovation in medical software systems[80]. - The company has developed innovative technologies, including a medical time-series data processing engine and a clinical event search engine, which have doubled the efficiency of disease-specific database construction[50]. Financial Management - The company has a total asset value of 2.49 billion yuan and a net asset value of 1.56 billion yuan as of the end of the reporting period[113]. - The company has accumulated undistributed losses of CNY 35.42 million at the consolidated level, which may affect future profit distribution[118]. - The company has a stock price decline risk with a provision for inventory impairment of CNY 58.57 million, primarily related to its medical information business[117]. - The company’s financing activities generated a net cash flow of CNY 95.04 million, an increase of 48.65% compared to CNY 63.93 million in the previous year[123]. - The company has a negative cash flow from investment activities of CNY 197.33 million, significantly higher than negative CNY 63.97 million in the previous year[123]. Employee Management - The company has a total of 1,865 employees, with 50 in the parent company and 1,815 in major subsidiaries[184]. - Among the employees, 1,539 are technical personnel, accounting for 82.4% of the total workforce[184]. - The company has established a salary management system to optimize its compensation structure and enhance employee motivation[186]. - The total remuneration for core technical personnel at the end of the reporting period was 3.9492 million RMB[173]. - The company has implemented a training program to enhance professional knowledge and skills among employees[187]. Future Outlook - Future guidance indicates a positive outlook, with expectations for continued growth in user data and market share[164]. - The company is investing 50 million in R&D for new technologies aimed at enhancing user experience[165]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online engagement by mid-2024[168]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 100 million allocated for potential deals[165].

Financial Performance - The total revenue for the reporting period was 600.72 million, a decrease of 14.85% compared to the previous year’s 695.18 million[2] - The net profit attributable to the parent company was revised to -256.12 million, a decrease of 70.77% from the previous estimate of -145.00 million[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was revised to -261.38 million, a decrease of 67.23% from the previous estimate of -156.00 million[5] - The basic earnings per share were reported at -1.09 yuan, a decrease of 908.70% compared to the previous year[2] - The weighted average return on net assets was -8.55%, a decrease of 16.94 percentage points from the previous year[2] Assets and Equity - Total assets at the end of the reporting period were 2,617.29 million, a decrease of 5.99% from the previous year’s 2,645.63 million[3] - The equity attributable to the parent company was 1,674.27 million, a decrease of 14.61% from the previous year’s 1,821.58 million[3] Accounting Issues - The company identified accounting errors in the financial statements for 2022 and 2023, leading to adjustments that reduced net profit and other financial metrics[6] - The company will enhance supervision and training on accounting standards to ensure the accuracy of future earnings forecasts[8] Investor Relations - The company expressed sincere apologies to investors for the impact of the earnings forecast and report corrections[8]

Financial Performance - The company's operating revenue for Q1 2025 was ¥101,199,221.48, representing a decrease of 17.43% compared to ¥122,559,648.25 in the same period last year[4] - The net profit attributable to shareholders was -¥17,433,344.55, worsening from -¥11,850,583.19 year-over-year[4] - The net cash flow from operating activities was -¥94,058,756.82, slightly improved from -¥96,963,002.49 in the previous year[4] - Total revenue for Q1 2025 was CNY 101,199,221.48, a decrease of 17.4% compared to CNY 122,559,648.25 in Q1 2024[18] - Net loss for Q1 2025 was CNY 25,433,828.07, compared to a net loss of CNY 16,002,665.06 in Q1 2024, representing an increase in loss of 58.9%[19] - The total comprehensive income for the first quarter of 2025 was -25,433,828.07 RMB, compared to -16,002,665.06 RMB in the first quarter of 2024, indicating a decline[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,417,566,990.38, down 2.80% from ¥2,487,288,265.92 at the end of the previous year[5] - The company's total assets decreased to CNY 2,417,566,990.38 from CNY 2,487,288,265.92, a decline of 2.8%[17] - Total liabilities decreased to CNY 922,834,172.17 from CNY 967,121,619.64, a reduction of 4.6%[16] - The company's total equity decreased to CNY 1,494,732,818.21 from CNY 1,520,166,646.28, a decline of 1.7%[17] Cash Flow - The cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[19] - Cash inflow from operating activities totaled 121,181,325.80 RMB in Q1 2025, down from 130,917,730.32 RMB in Q1 2024[21] - The net cash flow from investing activities was -10,332,107.19 RMB in Q1 2025, an improvement from -55,200,335.12 RMB in Q1 2024[22] - Total cash outflow from operating activities was 215,240,082.62 RMB in Q1 2025, compared to 227,880,732.81 RMB in Q1 2024[22] - The company received 77,476,300.00 RMB from financing activities in Q1 2025, down from 106,381,513.11 RMB in Q1 2024[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,860[9] - The top shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[10] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, accounting for 12.22%[10] - The company has a total of 9,861,786 shares held by Hongyun Jiukang Data Technology (Beijing) Co., Ltd., which is 7.17% of total shares[10] - The total number of shares held by the top 10 shareholders includes significant stakes from various investment funds, indicating strong institutional interest[11] Research and Development - Research and development expenses totaled ¥47,758,469.77, a decrease of 20.10% from ¥59,773,809.35, accounting for 47.19% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 34,429,266.72, up 7.3% from CNY 32,077,752.04 in Q1 2024[18] Management and Strategy - The company has committed to ensuring the accuracy and completeness of its financial information, with management taking legal responsibility for the report[2] - The company has not disclosed any significant new strategies or product developments during the earnings call[13] - The company plans to focus on enhancing data resources and technology development to drive future growth[18] - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its market position[19] Earnings Per Share - The diluted earnings per share for the period was -¥0.13, compared to -¥0.09 in the same period last year[5] - The company reported a basic and diluted earnings per share of -0.13 RMB for Q1 2025, compared to -0.09 RMB in Q1 2024[20] Other Information - The company reported non-recurring gains and losses totaling ¥526,350.33 for the period[7] - The company did not report any net profit from the merged entity prior to the merger, with previous net profit also reported as 0 RMB[20] - The company has not adopted new accounting standards or interpretations for the year 2025[23] - There are no other important reminders regarding the company's operational situation during the reporting period[13]

嘉和美康公告，2025年第一季度营收为1.01亿元，同比下降17.43%；净亏损1743.33万元，去年同期净 亏损1185.06万元。 ...

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

A股DRG/DIP概念股走强，创业惠康涨超6%，赛力医疗涨超5%，华平股份、嘉和美康、迪安诊断等涨 超3%。 ...

Investment Rating - The report maintains a "Buy" rating for the companies mentioned, indicating a positive outlook for their performance in the market [11][50]. Core Insights - The report highlights the launch of Alibaba's Qwen2.5-Omni, a new flagship multimodal model designed for comprehensive multimodal perception, capable of processing various inputs including text, images, audio, and video [4][19]. - DeepSeek-V3 has been released with significant performance improvements, becoming the strongest non-inference model, and is expected to accelerate AI applications in vertical fields [11][26]. - Anthropic has completed a $3.5 billion financing round, raising its valuation to $61.5 billion, showcasing the rapid growth and competition in the AI sector [36][37]. Summary by Sections 1. Computing Power Dynamics - Computing power rental prices remain stable, with specific pricing details provided for various configurations [18][21]. - Alibaba's Qwen2.5-Omni is positioned as a significant advancement in the AI landscape, emphasizing its capabilities in real-time interaction and multimodal processing [19][20]. 2. AI Application Dynamics - Gemini's search traffic increased by 6.85%, indicating growing interest in AI applications [25]. - The new version of DeepSeek, with 685 billion parameters, has shown remarkable performance improvements and is now open-sourced under the MIT license, enhancing its accessibility and potential for commercial applications [26][27]. 3. AI Financing Trends - Anthropic's recent funding round of $3.5 billion reflects the intense competition and rapid capital influx in the AI sector, with a total of over $4.5 billion raised in just three months [36][37]. 4. Investment Recommendations - The report suggests focusing on companies like 嘉和美康 (688246.SH), 科大讯飞 (002230.SZ), and others that are positioned to benefit from advancements in AI technology and applications [11][50].

证券代码：688246 证券简称：嘉和美康 公告编号：2025-022 嘉和美康（北京）科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持有的基本情况 截至本公告披露日，嘉和美康（北京）科技股份有限公司（以下简称"嘉和 美康"或"公司"）股东苏州赛富璞鑫医疗健康产业投资中心（有限合伙） （以下 简称"赛富璞鑫"）持有公司股份 4,736,268 股，占公司股份总数的 3.44%。股东 国寿成达（上海）健康产业股权投资中心（有限合伙）（以下简称"国寿成达"） 持有公司股份 16,812,069 股，占公司股份总数的 12.22%。上述股份为嘉和美康 首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流通。 公司于 2025 年 3 月 30 日收到国寿成达出具的《关于股东减持计划的告知 函》，因自身资金需求，股东国寿成达计划根据市场情况拟通过集中竞价方式和 大宗交易方式减持其持有的公司股份合计不超过 4,127,566 股 ...

截至本公告披露日，嘉和美康（北京）科技股份有限公司（以下简称"嘉和 美康"或"公司"）股东苏州赛富璞鑫医疗健康产业投资中心（有限合伙）（以下 简称"赛富璞鑫"）持有公司股份 4,736,268 股，占公司股份总数的 3.44%。股东 国寿成达（上海）健康产业股权投资中心（有限合伙）（以下简称"国寿成达"） 持有公司股份 16,812,069 股，占公司股份总数的 12.22%。上述股份为嘉和美康 首次公开发行并上市前取得的股份，且已于 2022 年 12 月 14 日起上市流通。 证券代码：688246 证券简称：嘉和美康 公告编号：2025-022 嘉和美康（北京）科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 减持计划的主要内容 公司于 2025 年 3 月 30 日收到赛富璞鑫出具的《关于股东减持计划的告知 函》，因股东流动性需求，股东赛富璞鑫计划根据市场情况拟通过集中竞价方式 减持其持有的公司股份合计不超过 2,063,783 ...

北京市中伦律师事务所 关于嘉和美康（北京）科技股份有限公司 法律意见书 二〇二五年三月 北京市中伦律师事务所 关于嘉和美康（北京）科技股份有限公司 法律意见书 致：嘉和美康（北京）科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》 （以下简称"《证券法》"）、中国证券监督管理委员会发布的《上 市公司股东大会规则》（以下简称"《股东大会规则》"）的规定，北京市中伦 律师事务所（以下简称"本所"）接受嘉和美康（北京）科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席公司 2025 年第二次临时股东大会 （以下简称"本次股东大会"），对本次股东大会的相关事项进行见证并出具法 律意见。 为出具本法律意见书，本所律师审查了公司提供的相关文件，该等文件包括 但不限于： 公司关于召开 2025 年第二次临时股东大会的通知的公告； 法律意见书 在本法律意见书中，本所律师仅对本次股东大会的召集、召开程序、出席会 议人员资格、召集人资格及会议表决程序、表决结果是否符合《公司法》《股东 大会规则》等法律、法规、规范性文件及公司章程的规定发表意见，不对会议审 议的议案内容 ...